Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint

Sanofi’s rilzabrutinib has found success and met the primary endpoint in the Phase III LUNA trial in heavily pre-treated immune thrombocytopenia (ITP) patients.

The French company also plans to file for approval of the rilzabrutinib in the US and the European Union (EU) in the second half of this year.